Business Context and Reporting Period
MediciNova, Inc. is a biopharmaceutical company developing therapies for serious diseases with unmet medical needs. Its primary programs include MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine), and MN-029 (denibulin). This unaudited Form 10-Q covers the quarter ended March 31, 2021. The company operates as a single segment and has no approved commercial products identified in the filing.
Key Financial Metrics
| Metric | Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 |
|---|---|---|
| Revenue | $4.0 million | $0 |
| Operating expenses | $4.2 million | $2.9 million |
| Operating loss | $0.2 million | $2.9 million |
| Net loss | $0.2 million | $2.7 million |
| Net loss per share | $0.00 | $0.06 |
| Net cash used in operating activities | $3.9 million | $2.9 million |
| Cash and cash equivalents at period end | $76.3 million | $61.3 million |
Reported operating margin was approximately negative 5.0% and net margin was approximately negative 4.7% in the 2021 quarter, based on reported revenue. Research, development and patent expense increased to $2.1 million from $1.3 million, while general and administrative expense increased to $2.1 million from $1.7 million. Stock-based compensation was $1.1 million, compared with $0.6 million in the prior-year quarter.
Financing activities provided $20.1 million, primarily from a private placement of 3,656,307 shares for approximately $20.0 million of net proceeds. Shares outstanding increased to 48,768,541 at March 31, 2021 from 45,024,560 at December 31, 2020. The filing does not disclose outstanding debt; total liabilities were $3.7 million, including $1.7 million of long-term deferred revenue and $0.2 million of deferred tax liabilities.
Working capital was $79.6 million at March 31, 2021. Management stated that available working capital was sufficient to fund operations at least through the end of 2022, although it could not assure that resources would fund all planned development programs.
Material Changes Versus the Prior Comparable Period
- Revenue increased by $4.0 million, entirely from two clinical development milestone payments under the Genzyme Agreement. The related receivable was collected in April 2021.
- Net loss narrowed by approximately $2.5 million, primarily because of the milestone revenue.
- Research and development expense rose by approximately $0.8 million, driven mainly by higher MN-166 clinical trial costs and performance-based stock compensation.
- General and administrative expense rose by approximately $0.4 million, primarily due to higher performance-based stock compensation.
- Operating cash use increased by approximately $1.0 million, largely because of the $4.0 million milestone receivable recorded at quarter-end.
- Cash increased by $16.3 million during the quarter, primarily because of the private placement, while common shares outstanding increased by approximately 3.7 million shares.
Guidance, Outlook, Risks, Contingencies and Unusual Items
- Management expects research and development costs to increase throughout 2021 as development programs progress and expects substantial net losses for the next several years.
- The company plans to advance MN-166 and MN-001 through company-funded, investigator-sponsored, government-funded and potentially partnered studies, and is considering strategic partnerships for development and commercialization.
- COVID-19 reduced patient visits at certain clinical sites, but management reported improving visits, continued enrollment and ongoing clinical and regulatory activities. Management did not expect a material negative effect on development plans, timelines or liquidity based on its assessment at the filing date.
- The FDA accepted the IND for MN-166 for prevention of COVID-19-related acute respiratory distress syndrome and informed the company that the proposed investigation could proceed.
- The $4.0 million of first-quarter revenue was unusual and non-recurring in nature because it resulted from milestone events under the legacy Genzyme Agreement rather than recurring product sales.
- The company remains dependent on clinical-trial success, regulatory approvals, additional financing or partnerships, third-party manufacturers and service providers, intellectual property rights, and the market acceptance and reimbursement of any future products.
- The company reported no material legal proceedings, no material changes to previously disclosed risk factors, and no material changes to contractual obligations during the quarter.
- Disclosure controls and procedures were assessed as effective at the reasonable assurance level, with no material change in internal control over financial reporting.
Important Facts for Investors to Verify
- Whether the $4.0 million Genzyme milestone revenue is repeatable or should be treated as a one-time event.
- Clinical enrollment, trial progress and readouts for MN-166, particularly in progressive multiple sclerosis, ALS and other targeted indications.
- The timing, scope and funding requirements of planned MN-001 and other pipeline programs.
- The company’s cash burn and whether the stated runway through the end of 2022 remains adequate as development spending increases.
- Potential future equity issuance, dilution and the remaining capacity under the $75.0 million 2019 at-the-market agreement.
- Regulatory outcomes, clinical-trial safety and efficacy, intellectual property developments, and the continuing effects of COVID-19.